An Expert Guide to What’s New and What’s Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma

Review the latest clinical trial data on approved and emerging targeted therapies for the management of relapsed/refractory follicular lymphoma with downloadable slides and an archived webcast from a live, expert-led symposium at ASH 2023, along with a companion FAQ commentary where experts answer audience questions from the live program.

Share

Program Content

Activities

CAR T-Cell Tx in R/R FL
CAR T-Cell Therapy in the Management of Relapsed/Refractory Follicular Lymphoma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2023

Bispecific Antibodies in R/R FL
Bispecific Antibodies in the Management of Relapsed/Refractory Follicular Lymphoma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2023

FL Tx Landscape and EZH2i in R/R FL
Follicular Lymphoma Treatment Landscape and EZH2 Inhibition in Relapsed/Refractory Disease
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2023

Activities

Expert guide on RR FL
Expert Guide: What’s New and Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma
Video
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2023

Expires: December 18, 2024

Activities

3L+ RR FL FAQs
Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma: Experts Answer Frequently Asked Questions
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2024

Faculty

cover img faculity

Julie M. Vose, MD, MBA

Newmann M. and Milde E. Harris Professor
Chief, Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

cover img faculity

Peter Martin, MD

Chief, Lymphoma Program
Professor of Medicine
Weill Cornell Medicine
Meyer Cancer Center
New York, New York

cover img faculity

Sonali M. Smith, MD, FASCO

Elwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
The University of Chicago
Chicago, Illinois

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Genentech, a member of the Roche Group; Genmab; Ipsen Biopharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc.

Genentech, a member of the Roche Group

Genmab

Ipsen Biopharmaceuticals Inc

Regeneron Pharmaceuticals, Inc